Cindy Driscoll
Plus aucun poste en cours
Profil
Cindy Driscoll worked as a Director of Finance at Nexaweb, Inc., a Controller at Gloucester Pharmaceuticals, Inc., a Principal at m-Qube, Inc. and Commerce5, Inc., and a Controller at TransMolecular, Inc. She then worked as a Vice President of Finance at Tokai Pharmaceuticals, Inc. from 2011 to 2017 and at Magenta Therapeutics, Inc. from 2020 to 2021.
Ms. Driscoll received an undergraduate degree from State University of New York College at Oswego in 1987 and an MBA from Suffolk University in 1991.
Anciens postes connus de Cindy Driscoll
| Sociétés | Poste | Fin |
|---|---|---|
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Director of Finance/CFO | 01/01/2013 |
| MAGENTA THERAPEUTICS | Director of Finance/CFO | 01/01/2019 |
Commerce5, Inc.
 Commerce5, Inc. Packaged SoftwareTechnology Services Commerce5, Inc. provides e-commerce channel management and automation software services. Its services include marketing, claims management, IT and call center support, and channel management. The company is headquartered in Aliso Viejo, CA. | Corporate Officer/Principal | - |
m-Qube, Inc.
 m-Qube, Inc. Packaged SoftwareTechnology Services m-Qube, Inc. develops mobile content messaging solutions. The company is a subsidiary of VeriSign, Inc. It was founded in 2001 and is located in Watertown, MA. | Corporate Officer/Principal | - |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Comptroller/Controller/Auditor | - |
Formation de Cindy Driscoll
| State University of New York College at Oswego | Undergraduate Degree |
| Suffolk University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
m-Qube, Inc.
m-Qube, Inc. Packaged SoftwareTechnology Services m-Qube, Inc. develops mobile content messaging solutions. The company is a subsidiary of VeriSign, Inc. It was founded in 2001 and is located in Watertown, MA. | Technology Services |
Commerce5, Inc.
Commerce5, Inc. Packaged SoftwareTechnology Services Commerce5, Inc. provides e-commerce channel management and automation software services. Its services include marketing, claims management, IT and call center support, and channel management. The company is headquartered in Aliso Viejo, CA. | Technology Services |
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Nexaweb, Inc.
 Nexaweb, Inc. Packaged SoftwareTechnology Services Nexaweb, Inc. develops application modernization software solutions. It provides products and service which simplify and transform client/server applications. The firm’s products include Nexacro and Nexaweb platform. The company was founded by Coach K. Wei in February 2000 and is headquartered in Burlington, MA. | Technology Services |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
